InterMune, Inc. (NASDAQ:ITMN) reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of EsbrietŪ (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease. Approximately 30,000-35,000 new IPF patients are diagnosed in Europe each year, with an estimated median survival of only two to five years. The announcement follows the recent marketing authorization of Esbriet in Europe and its first launch in Germany on 15 September.
Read the full article and disclaimer at: http://pennyomega.com/?p=17420
(ITMN, GBLHF.PK, MJGCF.PK, MASI, EXLS) Stock Highlights by PennyOmega.com
September 28th, 2011 at 12:57 pm